Drugmakers have greeted 2025, implementing price hikes for 583 products within the first two days of the new year, according ...

Protecting 340B means safeguarding the health and dignity of those who depend on it. The cost of losing 340B is far too high ...

Drug pricing is influenced by numerous factors, but technology has the potential to strike the critical balance between ...

Discover the Sun Pharma Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...

This industry’s lobbying juggernaut has its claws in both sides of the aisle in Congress. In 2022, pharmaceutical and health ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Stay updated with the Sun Pharma Stock Liveblog, your one-stop destination for real-time information and analysis of a ...

Findings show the impact of drug companies’ relentless price increases, underscoring the importance of the changes included ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

BofA analyst Alec Stranahan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $12 and keeps a ...